Journal of Clinical and Aesthetic Dermatology

AUG 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/870497

Contents of this Issue

Navigation

Page 61 of 67

62 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY August 2017 • Volume 10 • Number 8 J Clin Aesthet Dermatol. 2017;10(8):62–63 DERMATOLOGISTS COLLABORATE ON DATA- DRIVEN PEDIATRIC PSORIASIS RESEARCH Dr. Amy S. Paller, Professor and Chair of Dermatology at Northwestern University Feinberg School of Medicine presented findings from a study jointly conducted by the Pediatric Dermatology Research Alliance (PeDRA) and the European Pediatric Psoriasis Working Group (EPPWG) at the July World Congress of Pediatric Dermatology in Chicago. She discussed the soon-to-be-published study's findings, as well as how a retrospective analysis could inform a prospective registry. The study presented by Paller was a joint effort to understand dermatologists' experiences with using systemic drugs for pediatric psoriasis, and included a review of patient records of those treated with systemic therapy or phototherapy. The data collection examined demographics, clinical characteristics and severity, systemic agents used, treatment duration and efficacy, side effects, and reasons for discontinuation of medications. One of the most notable lessons learned from the retrospective analysis, claims Paller, is the need to optimize doctor- patient interaction for the purpose of data collection around a specific disease or treatment. * For more information, http://dermatologytimes.modernmedicine.com/dermat ology-times/news/dermatologists-collaborate-data- driven-pediatric-psoriasis-research MICRONEEDLING MAY PROVIDE ALTERATIVE TO LASERS A review by Dr. Mara Weinstein Velez on microneedling examined the potential for the treatment to replace laser therapy in certain clinical situations. The article explored microneedling treatments for three separate purposes: acne scarring, transdermal drug delivery, and facial rejuvenation. In regard to acne scarring, microneedling produced results similar to laser therapy, but with fewer side effects including redness and hyperpigmentation. In addition, microneedling is utilized during transdermal drug delivery by creating microscopic channels in the skin, yielding more effective application. Lastly, few studies have been conducted regarding microneedling and facial rejuvenation, but one has reported improvement of wrinkles at a range from 55 to 65 percent. More controlled trials are being conducted and will be published soon, says Dr. Weinstein Velez. * To read the press release, visit http://dermatologytimes.modernmedicine.com/dermat ology-times/news/microneedling-may-provide- alternative-lasers FDA APPROVES DRUG FOR ECZEMA The United States Food and Drug Administration (FDA) has approved the first injectable medicine to treat serious cases of eczema. On Tuesday, the FDA approved Dupixent for moderate or severe eczema. In three studies of the drug totaling 2,119 participants, one- third to two-thirds achieved clear or nearly clear skin after 16 weeks of treatment. About four in 10 had symptoms of itching decrease sharply, which improved sleep and reduced anxiety and depression. The drug is an antibody that patients inject just under the skin every two weeks. It binds to a specific protein to inhibit the immune system's inflammatory response. Side effects can include cold sores and inflammation of the eye and eyelid. * For more information, https://www.usnews.com/news/news/articles/2017- 03-28/fda-approves-1st-drug-for-moderate-severe- eczema-cases CALIFORNIA STUDY INDICATES INCREASED MELANOMA INCIDENCE A new analysis of non-Hispanic whites, published in the Journal of Investigative Dermatology, suggested that rising melanoma rates are real, and are not due to increased levels of detection. The new results, drawn from California, tracked incidence and stage at diagnosis of melanoma across different socioeconomic status groups. Across all groups, the researchers found increases not only in incidence, but also in advanced disease. Dr. Susan Swetter, from the Stanford University Medical Center and Cancer Institute, along with her colleagues, calculated incidence rates between 1998 and 2002, and 2008 and 2012, as well as tumor thickness and stage at diagnosis. Swetter explained that the findings "support a true real rise in incidence of melanoma across all thicknesses and stages, not just thinner, more indolent tumors that may be due to increased screening or diagnosis." * To read the study abstract, visit http://www.mdedge.com/edermatologynews/article/1 44148/melanoma/california-study-indicates-increased- melanoma-incidence RESEARCHERS TREAT SKIN INFECTIONS WITH NITRIC OXIDE-RELEASING NANOPARTICLES George Washington University (GW) researchers found that topically applied nitric oxide-releasing nanoparticles (NO-np) are a viable treatment for deep fungal infections of the skin caused by dermatophytes, for which the current standard of care is treatment with systemic antifungals. The researchers who carried out the study sought to find a way to overcome the need for systemic antifungals in the treatment of ringworm, due to the lengthy treatment durations, adverse interactions N EWS & TRENDS Exploring the internet for the latest reports on research, products, and trends in dermatology

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - AUG 2017